NCT02770508View on ClinicalTrials.gov

Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects

PHASE4CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

July 31, 2017

Study Completion Date

October 31, 2017

Conditions
HIV-1 Infection
Interventions
DRUG

darunavir/ritonavir

DRUG

Lamivudine

DRUG

emtricitabine-tenofovir(FTC/TDF)

Trial Locations (5)

1121

Consultorio Infectológico Dr. Pryluka, CABA

1155ADP

Hospital Cosme Argerich, CABA

1199ABB

Hospital Italiano, CABA

C1202ABB

Fundacion huesped, CABA

C1425AWK

Centro de Estudios Infectologicos SA (CTD Stamboulian), CABA

All Listed Sponsors
collaborator

Ministry of Science and Technology,Argentine

UNKNOWN

collaborator

National AIDS and STD programme,Argentine

UNKNOWN

collaborator

Richmond Laboratories

UNKNOWN

lead

Fundación Huésped

OTHER

NCT02770508 - Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects | Biotech Hunter | Biotech Hunter